Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Current Assets (2020 - 2025)

Mainz Biomed's Current Assets history spans 5 years, with the latest figure at $7.8 million for Q4 2024.

  • For Q4 2024, Current Assets fell 12.65% year-over-year to $7.8 million; the TTM value through Dec 2024 reached $7.8 million, down 12.65%, while the annual FY2024 figure was $7.8 million, 12.65% down from the prior year.
  • Current Assets for Q4 2024 was $7.8 million at Mainz Biomed, down from $9.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $18.4 million in Q4 2022 and bottomed at $186398.0 in Q4 2020.
  • The 5-year median for Current Assets is $9.0 million (2023), against an average of $9.0 million.
  • The largest annual shift saw Current Assets skyrocketed 5055.21% in 2021 before it crashed 51.14% in 2023.
  • A 5-year view of Current Assets shows it stood at $186398.0 in 2020, then surged by 5055.21% to $9.6 million in 2021, then soared by 91.26% to $18.4 million in 2022, then crashed by 51.14% to $9.0 million in 2023, then dropped by 12.65% to $7.8 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Current Assets are $7.8 million (Q4 2024), $9.0 million (Q4 2023), and $18.4 million (Q4 2022).